spacer
home > ebr > autumn 2017 > avoiding data overload
PUBLICATIONS
European Biopharmaceutical Review

Avoiding Data Overload

Automation is one way of coping with large numbers of repetitive cell screening assays and handling of biological specimens required by the pharmaceutical industry – in the search for new therapeutics, for example. Advances in robotics and computerised equipment, such as microscopes and other technologies, mean that automation is now a more affordable possibility. Full-scale systems incorporate coordinated hardware for practical sample handling protocols linked to software packages for data handling and analysis.

The ability to standardise multiple procedures in automated protocols is particularly advantageous, allowing compliance with enforced statutory regulations of laboratory and manufacturing practice. Such automated workflows have the ability to deliver a high volume of reproducible, high-quality data while saving time and increasing efficiency and accuracy. However, while automation offers many benefits, scientists can often underestimate the significant data load generated by robotic workflows. This can quickly become unmanageable, slowing processes, producing backlogs and ultimately preventing the system from reaching the full capacity for which it was designed.

Careful Planning

The installation of automated systems in a lab is driven by a need to increase output, improve efficiency and, thereby, provide a good return on investment. A build-only solution concentrating on hardware design may appear to be cost-effective, but planning for data handling and analysis during the installation period can save time and expense in the future. The mechanical and computational intricacy of automation systems can be let down by overly complicated operating systems. However, platforms controlled by easy-to-use touch screen interfaces – which require minimal operator training and provide logical step-by-step instructions – are available.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rob Harkness is a Business Development Manager at Peak Analysis and Automation. Here, he is responsible for business and technical development, which involves designing and delivering lab software solutions to the life sciences sector. Rob has over 15 years’ experience in the life sciences automation market and is responsible for leading groups through the full product lifecycle of lab automation products, ensuring efficient integration through analysing requirements and recommending appropriate solutions.
spacer
Rob Harkness
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Announces Success of Integrated Discovery Project with ENYO Pharma

Wilmington, Mass and Lyon, France, Nov. 28, 2017 - Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration. Together, the companies identified the mode of action of ENYO Pharma’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

5th Biennial Biosimilars & Biobetters Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th – 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement